Novo Nordisk's New Hypoglycemic Drugs Novolin Launches in China

Lowering blood sugar is also prone to hypoglycemia, which is a contradiction that has always existed in the course of diabetes treatment. On the 9th, the new diabetes drug Novozymes (Lilaglutide Injection) officially listed in the country will break through this treatment "difficulty."

Novozymes is currently the world's first human glucagon-like peptide analogue (human GLP-1 analogue) and has been marketed in more than 30 countries around the world. Yang Wenying, director of the Department of Endocrinology at the China-Japan Friendship Hospital of the Ministry of Health, led the registration study of the drug in China.

Yang Wenying said that the incretin GLP-1 (glucagon-like peptide 1) is a hormone that stimulates insulin secretion in the gastrointestinal tract. The hormones of patients with type 2 diabetes have varying degrees of damage, and Novozymes mimics human self-secreted GLP-1.

She pointed out that the GLP-1 hormone is glucose-dependent, which means that only when the glucose level is increased, GLP-1 will be activated to play a role, if the blood sugar is normal, if there is more GLP-1 injection, it will not Play a role. This hypoglycemic principle allows Novozymes to reduce hypoglycemia while reducing blood sugar.

At present, there are more than 92 million adult patients with type 2 diabetes in our country. According to Ji Linong, chairman of the Diabetes Branch of the Chinese Medical Association and director of the Department of Endocrinology at the People's Hospital of Peking University, nearly 80 percent of patients in China lack control of blood glucose control. This is related to the adverse reaction of hypoglycemia in diabetes treatment and the lack of positive treatment of patients with diabetes. Novozymes only needs to be injected once a day, and it can be selected at any time of the day. This will help improve treatment compliance and increase the rate of blood glucose compliance.

In addition, the study also showed that Novozymes can also reduce the patient's weight and blood pressure, and also have a positive effect on reducing the risk of cardiovascular disease, and also have protective effects on pancreatic islet β cells.